9 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Adoptive engineered T cell Trials to Achieve Cancer Killing (ATTACK)
Date du début: 1 déc. 2012, Date de fin: 30 nov. 2017,
The aim of this research is to exploit technology for nucleic acid delivery through the clinical testing of adoptive engineered T cells to treat cancer. Recent innovative developments in cancer gene-immunotherapy have led to very encouraging early clinical results. However, the use of engineered T cells is a challenging and complex field with further development and more proof-of-principle trials ...
Voir le projet
16
Participants partenaires
TERMINÉ
"Identification, homing and monitoring of therapeutic cells for regenerative medicine – Identify, Enrich, Accelerate" (IDEA)
Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,
"Regenerative medicine focuses on repairing or replacing tissue or organ function lost due to damage or congenital defects using appropriate cells for therapy that have healing capacities like stem cells or progenitor cells. Although regenerative medicine has the potential for more effective therapeutic interventions major improvement in three areas are still needed for a wider establishment of su ...
Voir le projet
11
Participants partenaires
TERMINÉ
A European Platform for Translational Cancer Research (EUROCANPLATFORM)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,
Europe has a number of advantages as regards developing translational cancer research, yet there is no clear European strategy to meet the increasing burden posed by cancer. The FP6 Eurocan+Plus project analysed the barriers underlying the increasing fragmentation of cancer research and stressed the need to improve collaboration between basic/preclinical and comprehensive cancer centres (CCCs), in ...
Voir le projet
29
Participants partenaires
TERMINÉ
Cancer Associated Fibroblasts (CAF) Function in Tumor Expansion and Invasion (CAFFEIN)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2016,
"Aim of the CAFFEIN network is to provide 10 early stage researchers (ESRs) and 2 exprerienced researchers (ERs) with excellent training in an industry relevant area of cancer research, complementary skills required for pharmaceutical industry, and knowledge in setting up biomedical start-up companies. To this end, the network comprises two full industrial partners: the established pharmaceutical ...
Voir le projet
11
Participants partenaires
TERMINÉ
Combining epidemiology and radiobiology to assess cancer risks in the breast, lung, thyroid and digestive tract after exposures to ionizing radiation with total doses in the order of 100 mSv or below (EpiRadBio)
Date du début: 1 avr. 2011, Date de fin: 31 mars 2015,
Recent epidemiological studies suggest that cancer risk after exposures with doses comparable to the dose limits for occupationally exposed workers may be larger than assumed by ICRP in the derivation of these limits. The value of cancer risk from such exposures and its dependence on tissue, radiation type and individual factors is largely unknown. The innovative approach proposed here combines ep ...
Voir le projet
23
Participants partenaires
TERMINÉ
Painting the landscape of translational control of gene expression through meta-analysis of genome wide data sets (TRANSLATOMICS)
Date du début: 1 avr. 2011, Date de fin: 31 mars 2015,
Translational control determines the rate at which mRNAs are synthesized into proteins; regulates biological processes ranging from apoptosis to memory; and shows deregulation in diseases such as fibrosis and cancer. In cancer, dysregulated translational control is associated with worse prognosis in most sold cancer. Despite this, integrated genome wide knowledge of translational control and its r ...
Voir le projet
1
Participant partenaire
TERMINÉ
Genome-based biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer (RESPONSIFY)
Date du début: 1 févr. 2012, Date de fin: 31 janv. 2015,
Individualisation of cancer therapy based on standardized biomarker assays is one of the most demanding challenges in cancer medicine. In the RESPONSIFY consortium, we will integrate information on response prediction from different breast cancer types and methodologies into biomarker tests for targeted therapies in the clinical routine setting. Those tests will be developed for commercialisation ...
Voir le projet
14
Participants partenaires
TERMINÉ
Unraveling the therapeutic potential of cancer-associated fibroblasts (CAF) in cancer using cell-specific targeting technology (CAFTECH)
Date du début: 1 août 2011, Date de fin: 31 juil. 2013,
"Cancer is a major health burden affecting 12-million people each year world-wide. Tumor growth is not only determined by tumor cell malignancy but also by the tumor microenvironment. Cancer-associated fibroblasts (CAF) are key cell type in the tumor microenvironment influencing tumor initiation, angiogenesis, metastasis and tumor drug response. CAF strongly express platelet-derived growth factor ...
Voir le projet
1
Participant partenaire
TERMINÉ
European Consortium for Anticancer Antibody Development (EUCAAD)
Date du début: 1 mai 2008, Date de fin: 30 avr. 2012,
Cancer is the second leading cause of death in European countries, and one of the most imminent health problems in the developed world. Innovative, so-called targeted therapies are urgently needed that aim specifically at cancer cells or to cells of the stroma that support tumor growth. The ultimate goal of a targeted therapy is to increase anti-tumor efficacy with lowest possible side effects. R ...
Voir le projet